Medicated thread moxibustion for alopecia areata
A case report

Yi-Mei Zhang, MSc\textsuperscript{a}, Cui-Hong Liu, MD\textsuperscript{b}, Yong-Cheng Wang, MD\textsuperscript{c}, Hong-Li Teng, MD\textsuperscript{d}, Xian-Liang Meng, MSc\textsuperscript{e}, Xing-Jun Han, MSc\textsuperscript{f,\textsuperscript{g}}


declaration of interest to disclose.
\textsuperscript{a} Department of Acupuncture and Moxibustion, Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, \textsuperscript{b} Department of Ultrasound Diagnosis and Treatment, Provincial Hospital Affiliated to Shandong University, \textsuperscript{c} Department of Cardiovascular, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, \textsuperscript{d} Department of Toxicology, Guangxi International Zhuang Medical Hospital, Nanning, \textsuperscript{e} Department of Cardiovascular, Taian Hospital of Traditional Chinese Medicine, Taian, \textsuperscript{f} Department of Prevention and Health Centres, Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.

* Correspondence: Xing-jun Han, Prevention and Health Centres, Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jingba Road No.1, Jinan 250001, China (e-mail: hanzhengjun1228@hotmail.com)

Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Zhang YM, Liu CH, Wang YC, Teng HL, Meng XL, Han XJ. Medicated thread moxibustion for alopecia areata: A case report. Medicine 2019;98(49):e17793.

Received: 23 May 2019 / Received in final form: 11 September 2019 / Accepted: 3 October 2019
http://dx.doi.org/10.1097/MD.0000000000017793

1. Introduction

Alopecia areata (AA) is a type of nonscarring and immunemediated disease-causing patchy hair loss with no obvious epidermal changes, which often occurs in the parts of the body covered with hair. According to statistics, the lifetime incidence rate of AA is approximately 1.7%\textsuperscript{1,2}; there is a higher incidence in younger patients, but there is no significant gender difference.\textsuperscript{3,4} Although hair loss does not directly threaten the life span, it can cause severe mental burden and social stress because it impairs beauty.\textsuperscript{5} Currently, the major methods for treating AA include nonspecific broad immunosuppressant medications given systemically or locally to dampen immune cell attack or contact sensitizers to redirect autoimmune attack.\textsuperscript{6} However, while these methods offer effective treatment for AA, they also have negative side effects for patients.\textsuperscript{7} Additionally, the prognosis of the disease is unpredictable and highly variable. Furthermore, the etiology and pathological mechanism of AA have not been fully elucidated, which creates obstacles to effective treatment strategies and leads to huge medical needs.\textsuperscript{8} Here, we report a male patient who presented with spontaneous, progressive hair loss lasting 6 months; the patient achieved very good clinical benefits after being treated with the medicated thread moxibustion method of Zhuang medicine.
2. Case report

A 36-year-old male visited our department on August 13, 2018 with a main complaint of loss of hair loss on the top of the head with insomnia, depression, anxiety, and a series of related symptoms after his father died suddenly approximately half a year prior. The clinical examination showed a nonscarring alopecia plaque, which was approximately 5.0 × 3.2 cm in size; there was no involvement beyond the top of the head. The damaged part of the hair loss area had a bright skin color and a clear boundary with its surroundings. By asking for detailed information about his illness, we learned that the patient had no family history or other related illnesses, although the patient did have occasional irregular habits and alcoholism in the 6 months prior. To further clarify the etiology, routine examinations, including thyroid color Doppler ultrasound detection, and a full blood count, were performed to exclude other primary diseases; all results were normal. Based on the above information, the patient refused to accept any medication, including oral or external options. Therefore, we tried to treat the patient with the medicated thread moxibustion method of traditional Zhuang medicine.

After full communication with the patient, the patient signed an informed consent form for the publication of the case. We chose to use the version of II twine with a diameter of 0.7 mm (the medicated threads were provided by Guangxi International Zhuang Medical Hospital), a lighter and an alcohol lamp (Fig. 1A and B). The first affected skin area is often chosen as the primary acupoint. Here, we chose acupoints including the Kuihua acupoint (dependent on the shape and size of local skin lesions on the body surface, a group of acupoints were selected along the periphery and midpoint, which were sunflower-shaped), Zusanli (ST 36), Xuehai (SP 10), Baihui (DU 20), and Taichong (LR 3). The procedure included the following 4 main steps.

(1) Arranging: the loose thread was tightly wound (Fig. 1C).
(2) Holding: the end of a thread was grabbed with the forefinger and thumb of the right hand 1 to 2 cm were exposed (Fig. 1D).
(3) Igniting: the exposed end was lit with an alcohol lamp. If there was a flame, it was extinguished; only a bead-like sparkle was needed on the top of the medicated thread (Fig. 1E).
(4) Moxibustion: the acupoints were aligned with the bead-like sparkle on the thread; the thumb and index finger gripped the end of the thread in a steady and agile manner with wrist and thumb flexion movements (Fig. 1F).

Figure 1. Method and material of medicated thread moxibustion in Zhuang medicine (A–F).
When the sparkle was extinguished, the thread was picked up immediately; this called 1 Zhuang. Repeating this sequence of steps, moxibustion was performed at the above 5 acupoints in turn. Each acupoint was cauterized 2 times, once every 2 days for 4 weeks. After moxibustion on the day of treatment, the patients were told to not scratch or wash their heads with water. Additionally, the patient was instructed to stay relaxed throughout the treatment period and to participate in the follow-up for 3 months.

After the initial treatment, the area of hair loss did not continue to expand, and no new areas of hair loss mass appeared (Fig. 2A). After 1 week of treatment, a small amount of hair began to appear sporadically from the hair follicles in the hair loss area. The color and thickness of the hair were similar to those of fine hair, and the hairs could only be seen in bright light (Fig. 2B). After the patient received medicated thread moxibustion for 2 weeks, hairs of different lengths and uneven colors were observed to cover the patchy AA area (Fig. 2C). After 3 weeks of topical treatment with medicated thread moxibustion, the patchy AA area was covered with hair of different lengths and colors (Fig. 2D). At the end of the last course of treatment, the hair follicles in the hair loss area were almost covered with hair. Although the density, thickness, and color were not exactly the same as the surrounding hair, the hair was still in the process of regeneration (Fig. 2E). After the medicated thread moxibustion treatment, we stopped moxibustion and followed the patient closely for 3 months (Fig. 2F). Additionally, a hair pulling procedure was conducted on newly grown hair at the end of each course and during the follow-up period, and the results were negative. Informed written consent was obtained from the patient for publication of this case report and accompanying images. All procedures involving the patient were conducted in accordance with the ethical standards of the Ethics Committee of the Second Affiliated Hospital of Shandong University of Chinese Medicine.

3. Discussion
AA is an autoimmune disease characterized by an infiltration of T cells and the production of inflammatory factors, the most typical
manifestation of which is a sudden exfoliation of scalp plaques. Studies have shown that T-helper 17 cells (Th17) and regulatory T cells (Tregs) play important roles in the pathogenesis of autoimmune diseases. Th17 cells can promote inflammation by releasing cytokines, while an increase in Treg cells can limit the activity of inflammatory factors. Th17 cells is a unique subset of T-helper cells that can produce cytokines such as interleukin (IL)-17A, IL-17F, IL-21, IL-22, IL-6, and tumor necrosis factor-a (TNF-a). Relevant research shows that IL-17, TNF-a, transforming growth factor-β (TGF-β) and other pro-inflammatory factors are significantly increased in the pathogenesis of AA. Atwa et al. found that IL-17 and TNF-a were positively correlated with the severity of AA, while the IL-22 level stasis, and abnormalities of these cells may lead to autoimmune and immunopathological diseases. Tregs are a special subset of T-helper cells that can produce cytokines such as IL-10. Researchers have pointed out that the collapse of immune privilege of hair bulbs during growth due to the impairment of Treg or TGF-β function is the key mechanism leading to AA. Zoller et al found that the CD4+CD25+ Treg level was significantly decreased in a C3H/HeJ AA mouse model. Tembhi et al found that the serum level of TGF-B1 was decreased in AA patients, suggesting that Treg function was deficient. Consequently, the T cell-mediated immunenhancement and Treg deficiency-induced decline in immune tolerance are important pathogenesis of AA.

Medicated thread moxibustion is a traditional national therapy that uses a variety of Zhuang medicine methods involving the preparation of special ramie thread that has been soaked in liquid and direct moxibustion of the corresponding acupoints or lesions of the human body after ignition. Medicated thread moxibustion has unique thermal and inflammatory factors. Th17 cells are a unique lineage of CD4 T cells that regulate T-helper 17 cells: possible synergistic culprits in the pathogenesis of Alopecia Areta and regulates T-cell effector cytokines in in vitro and in vivo experiments. Therefore, in this study, the mechanism of mediated thread moxibustion in the treatment of AA may be related to the regulation of Th17 or Treg cells, and relevant validation will be implemented in future experiments.

Author contributions
Conceptualization: Yi-Mei Zhang, Cui-Hong Liu, Yong-Cheng Wang, Xing-Jun Han.
Data curation: Yi-Mei Zhang, Cui-Hong Liu, Yong-Cheng Wang, Hong-Li Teng, Xian-Liang Meng.
Formal analysis: Yi-Mei Zhang, Cui-Hong Liu, Yong-Cheng Wang.
Funding acquisition: Hong-li Teng.
Investigation: Yi-Mei Zhang, Yong-Cheng Wang, Hong-Li Teng, Xian-Liang Meng.
Methodology: Yi-Mei Zhang, Cui-Hong Liu, Yong-Cheng Wang, Hong-Li Teng, Xian-Liang Meng.
Resources: Yi-Mei Zhang, Cui-Hong Liu, Yong-Cheng Wang, Hong-Li Teng, Xian-Liang Meng.
Software: Yi-Mei Zhang, Cui-Hong Liu, Yong-Cheng Wang, Xian-Liang Meng.
Supervision: Xing-Jun Han.
Validation: Hong-li Teng, Xing-Jun Han.
Visualization: Yi-Mei Zhang, Cui-Hong Liu, Yong-Cheng Wang, Xing-Jun Han.
Writing – original draft: Yi-Mei Zhang, Cui-Hong Liu, Yong-Cheng Wang.
Writing – review and editing: Yi-Mei Zhang, Cui-Hong Liu, Yong-Cheng Wang, Xing-Jun Han.

References
[1] Betz RC, Petukhova L, Ripke S, et al. Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci. Nat Commun 2013;5:5966.
[2] Ji C, Liu S, Zhu K, et al. HLA-DRB1 polymorphisms and alopecia areata disease risk: a systematic review and meta-analysis. Medicine (Baltimore) 2018;97:e11790.
[3] Yoshimatsu T, Furukawa F. Modified immunotherapy for alopecia areata. Autoimmun Rev 2016;15:664–7.
[4] Lim SK, Lim CA, Kwon B, et al. Low-dose systemic methotrexate therapy for recalcitrant alopecia areata. Ann Dermatol 2017;29:263–7.
[5] Gonul M, Cemil BC, Ayyaz HH, et al. Comparison of quality of life in patients with androgenetic alopecia and alopecia areata. An Bras Dermatol 2018;93:651–8.
[6] Elela MA, Gawdat H, Hegazy RA, et al. B cell activating factor and T helper 17 cells: possible synergistic culprits in the pathogenesis of Alopecia Areta. Arch Dermatol Res 2016;308:115–21.
[7] Gang F, Pan C, Hescheng W, et al. Effect of Zhangu medicine mediated thread moxibustion on protomics in serum of postherpetic neuralgia patient with Herpes zoster. Pak J Pharm Sci 2017;30:1063–7.
[8] Jalili RB, Kilani RT, Yanyuan L, et al. Fibroblast cell-based therapy prevents induction of alopecia areata in an experimental model. Cell Transplant 2018;27:994–1004.
[9] Han YM, Sheng YY, Xu F, et al. Imbalance of T-helper 17 and regulatory T cells in patients with alopecia areata. J Dermatol 2015;42:981–8.
[10] Niu Q, Cai B, Huang ZC, et al. Disturbed Th17/Treg balance in patients with rheumatoid arthritis. Rheumatol Int 2012;32:2731–6.
[11] Bettelli E, Oukka M, Kuchroo VK. Th-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007;8:345–50.
[12] Park H, Li Z, Yang XO, et al. A distinctive lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005;6:1133–41.
[13] Liang SC, Tan XY, Luxenberg DP, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006;203:2271–9.
[14] Ouyang W, Kolis JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008;28:454–67.
[15] Atwa MA, Youssef N, Bayoumy NM. T-helper 17 cytokines (interleukins 17, 21, 22, and 6, and tumor necrosis factor-β) in patients with alopecia areata: association with clinical type and severity. Int J Dermatol 2016;55:666–72.
[16] Tojo G, Fujimura T, Kawano M, et al. Comparison of interleukin-17-producing cells in different clinical types of alopecia areata. Dermatology 2013;227:78–82.

[17] Tanemura A, Oso N, Nakano M, et al. Alopecia areata: infiltration of Th17 cells in the dermis, particularly around hair follicles. Dermatology 2013;226:333–6.

[18] Kasumagic-Halilovic E, Prohic A, Cavaljuga S. Tumor necrosis factor-alpha in patients with alopecia areata. Indian J Dermatol 2011;56:494–6.

[19] Zhou L, Ivanov II, Spolski R, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007;8:967–74.

[20] Sakaguchi S. Regulatory T cells. Springer Semin Immunopathol 2006;28:1–2.

[21] Aftahi B, Lombardi G, Lechler R, et al. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 2007;148:32–46.

[22] Paus R, Itó N, Takigawa M, et al. The hair follicle and immune privilege. J Investig Dermatol Symp Proc 2003;8:188–94.

[23] Zoller M, McElwee KJ, Engel P, et al. Transient CD44 variant isoform expression and reduction in CD44(+/+)CD25(+) regulatory T cells in C57BL/6J mice with alopecia areata. J Invest Dermatol 2002;118:983–92.

[24] Tembhire MK, Sharma VK. T-helper and regulatory T-cell cytokines in the peripheral blood of patients with active alopecia areata. Br J Dermatol 2013;169:543–8.

[25] Li G. Therapeutic effect of Zhuang medicine medicated thread moxibustion on asthma of lung deficiency type. Chin Acupunct Moxib 2005;25:181.

[26] Cervera L, Gutierrez-Granados S, Martinez M, et al. Effect of medicated thread moxibustion of Zhuang traditional medicine on T cell subsets in peripheral blood of patients with Herpes zoster. J Chengdu Univ Tradit Chin Med 2013;166:152–65.

[27] Zhang LC, Xiao HR, Wu YX, et al. The significance of IL-17F in the intervention of ulcerative colitis by thread-point moxibustion of Zhuang Medicine. Jiangxi Tradit Chin Med 2016;47:54–6.